HC Wainwright Analysts Lift Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at HC Wainwright increased their Q3 2026 EPS estimates for shares of Corcept Therapeutics in a research note issued on Thursday, July 30th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.78 for the quarter, up from their previous forecast of $0.34. HC Wainwright has a “Buy” rating and a $165.00 price objective on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.13 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $1.31 EPS, FY2026 earnings at $2.15 EPS, Q1 2027 earnings at $0.74 EPS, Q2 2027 earnings at $1.03 EPS, Q3 2027 earnings at $1.32 EPS, Q4 2027 earnings at $1.40 EPS and FY2027 earnings at $3.95 EPS.

CORT has been the topic of a number of other research reports. UBS Group set a $135.00 target price on Corcept Therapeutics in a report on Thursday, May 28th. Weiss Ratings restated a “hold (c-)” rating on shares of Corcept Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen raised shares of Corcept Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday. Wolfe Research lowered shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a research note on Monday, July 27th. Finally, Piper Sandler reiterated an “overweight” rating and set a $165.00 target price (up from $88.00) on shares of Corcept Therapeutics in a research note on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $119.17.

Corcept Therapeutics Stock Down 2.7%

Shares of Corcept Therapeutics stock opened at $109.80 on Monday. The firm has a market cap of $11.87 billion, a P/E ratio of 261.43 and a beta of 0.45. Corcept Therapeutics has a fifty-two week low of $28.66 and a fifty-two week high of $122.21. The business has a 50-day moving average price of $86.81 and a 200 day moving average price of $57.96.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. The business had revenue of $256.15 million for the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a net margin of 6.52% and a return on equity of 8.26%. The company’s revenue for the quarter was up 31.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.29 EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CORT. First Trust Advisors LP lifted its stake in Corcept Therapeutics by 213.5% during the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after buying an additional 1,480,059 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Corcept Therapeutics by 546.9% in the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after purchasing an additional 1,274,215 shares during the period. Geode Capital Management LLC grew its position in Corcept Therapeutics by 38.0% in the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after purchasing an additional 734,646 shares during the last quarter. Norges Bank bought a new position in shares of Corcept Therapeutics during the 4th quarter worth about $24,213,000. Finally, UBS Group AG increased its holdings in shares of Corcept Therapeutics by 413.8% during the 3rd quarter. UBS Group AG now owns 549,938 shares of the biotechnology company’s stock worth $45,705,000 after purchasing an additional 442,898 shares during the period. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $93.13, for a total value of $1,862,600.00. Following the sale, the insider directly owned 3,985 shares of the company’s stock, valued at $371,123.05. This trade represents a 83.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Sean Maduck sold 25,000 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $88.35, for a total value of $2,208,750.00. Following the sale, the insider directly owned 9,755 shares in the company, valued at approximately $861,854.25. This trade represents a 71.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 360,000 shares of company stock worth $30,228,250. Corporate insiders own 20.70% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.